Article Sidebar
Published:
Jan 20, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Computational design of phosphoinositide 3-kinase gamma (PI3Kg) inhibitors as a newer therapy for rheumatoid arthritis
Abstract
Purpose: To develop a potential therapy for rheumatoid arthritis (RA) by altering factors involved in the pathogenesis of the disease.
Methods: Molecular docking simulation-based virtual screening was performed against phosphoinositide-3-kinase gamma (PI3Kg) to identify potential leads that may serve as anti-rheumatoid arthritic agents through their interactions and binding energies with the target receptor, followed by their optimization for improvement of their pharmacokinetics and toxicity profiles.
Results: Molecular docking simulation-based virtual screening and computational toxicity profiling predicted that the lead compounds ZINC04376856, ZINC01729526, ZINC01045089, ZINC03954520, ZINC01738764, and ZINC01163259 were potent PI3Kg inhibitors.
Conclusion: These lead compounds exert potent inhibitory effects on human PI3Kg receptor. Thus, they need to be experimentally validated for use in the development of novel drugs for treating RA in humans.
